Article Sidebar

Submitted
November 12, 2024
Accepted
November 12, 2024
Published
November 12, 2024
Download
PDF
Statistic
Read Counter : 411 Download : 288

Main Article Content

Abstract

Background: This article examines the pathophysiological processes behind health problems
resulting from tobacco use in individuals with HIV, as well as the potential interactions between
these mechanisms and HIV infection. HIV-infected persons experience a more pronounced
health impact from smoking tobacco in comparison to others who are not infected. Smoking in
people living with HIV (PLWH) is influenced by various factors, such as the presence of mental
health conditions, alcohol and drug consumption, the quality of their health-related well-being,
smoking habits within their social circles, and limited healthcare accessibility. People living with
HIV (PLWH) who smoke are more susceptible to many infections connected with HIV and other
health issues, such as a diminished response to antiretroviral drugs, a weakened immune system,
lower cognitive abilities, poor lung function, and cardiovascular disease.
Aim: The objective of the study is to examine the correlation between smoking and the
probability of contracting HIV. Smoking is recognized to impair the immune system and
heighten susceptibility to infections and chronic illnesses, which can be especially harmful to
individuals already impaired by HIV.
Methods: The journals were collected using the systematic literature review approach,
adhering to the guidelines developed by the Preferred Reporting Items of Systematic Reviews
and Meta-Analyses (PRISMA). The procedure consists of four phases: identification, screening,
eligibility, and inclusion for satisfactory outcomes. The literature review was carried out by
systematically scanning scientific papers using internet-based databases like Google Scholar,
Science Direct, BMJ Open, and Lontar UI. The search was conducted using exact combinations
of keywords. The topics of interest are HIV, tobacco usage, and those who have HIV and engage
in smoking.

Keywords

HIV Smoking Identify health risks

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Arrildt KT, Joseph SB, Swanstrom R. The HIV-1 env protein: a coat of many colors. Curr
  2. HIV/AIDS Rep. 2012; 9:52–63.
  3. Atkins MC, Carlin EM, Emery VC, Griffiths PD, Boag F. Fluctuations of HIV load in semen
  4. of HIV positive patients with newly acquired sexually transmitted diseases. BMJ 1996;
  5. :3412.
  6. Bourlet T, Cazorla C, Berthelot P, Grattard F, Cognasse F, Fresard A, Defontaine C, Lucht
  7. FR, Genin C, Pozzetto B. Compartmentalization of HIV-1 according to antiretroviral therapy:
  8. viral loads are correlated in blood and semen but poorly in blood and saliva. AIDS. 2001;
  9. :284–285.
  10. Centers for Diseases Control and PreventionVital signs: current cigarette smoking among
  11. adults aged ≥18 years—United States, 2005–2010., MMWR Morb Mortal Wkly Rep, 2011, vol.
  12. (pg. 1207-12).
  13. Centers for Disease Control and Prevention and Prevention, (September 10, 2005); Updated
  14. U.S. Public Health Service Guidelines for the Man- agement of Occupational Exposures to HIV
  15. and Recommendations for Post-exposure Prophylaxis, 54:(RR09):1–17.
  16. Chitwood DD, McCoy CB, Inciardi JA, McBride DC, Comerford M, Trapido E, McCoy HV,
  17. Page JB, Griffin J, Fletcher MA. HIV seropositivity of needles from shooting galleries in south
  18. Florida. Am J Public Health 1990; 80:150–2.
  19. CoovadiaH.Antiretroviralagents—howbesttoprotectinfantsfromHIV and save their mothers
  20. from AIDS. N Engl J Med 2004; 351:289–92.
  21. Cosgrove KP, Wang S, Kim SJ, McGovern E, Nabulsi N, Gao H, et al. Sex differences in the
  22. brain’s dopamine signature of cigarette smoking. J Neurosci. 2014; 34:16851–5.
  23. CrothersKGouletJLRodriguez-BarradasMCImpact of cigarette smoking on mortality in HIV
  24. positive and HIV-negative veteransAIDS Educ Prev2009213 Suppl405319537953.
  25. Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and
  26. counting. Psychosom Med 2008; 70:606–11.
  27. Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL, Faucett C, Fletcher MA,
  28. Kleinman SH, Operskalski EA, et al. Infection with human immunodeficiency virus type 1
  29. (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med 1990;
  30. :7339.
  31. Drummond MB, Kirk GD, Astemborski J, et al. Association between obstructive lung
  32. disease and markers of HIV infection in a high-risk cohort, Thorax, 2012, vol. 67 (pg. 309-14).
  33. Faria NR, Rambant A, Suchard MA, Baele G, Bedford T, Ward MJ, Tatem AJ, Sousa JD,
  34. Arinaminpathy N, Pépin J, Posada D, Peeters M, Pybus OG, Lemey P. HIV epidemiology. The
  35. early spread and epidemic ignition of HIV-1 in human populations. Science. 2014; 346:56–61.
  36. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang
  37. L, Nanda K, Rountree W. SAVVY vaginal gel (C31G) for prevention of HIV infection: a
  38. randomized controlled trial in Nigeria. PLoS ONE 2008; 23:3: e1474.
  39. Fry DE. Occupational risks of blood exposure in the operating room. Am Surg
  40. ; 73:637–46.
  41. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur
  42. LO, Peeters M, Shaw GM, Sharp PM, Hahn BH. Origin of HIV-1 in the chimpanzee Pan
  43. troglodytes troglodytes. Nature. 1999; 397:436–441.
  44. Gingo MR, George MP, Kessinger CJ, et al. Pulmonary function abnormalities in HIV
  45. infected patients during the current antiretroviral therapy era, Am J Respir Crit Care Med, 2010, vol. 182 (pg. 790-6).
  46. Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, Shattock RJ, McGowan I, Margolis
  47. L, Anton P. HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo
  48. with CCR5- and CXCR4tropic HIV-1. AIDS. 2007; 21:12631272. A
  49. Helleberg M Afzal S Kronborg G Mortality attributable to smoking among HIV-1-infected
  50. individuals: nationwide, Dis201356572773423254417. population-based cohort studyClin Infect
  51. Hitchman SC, Fong GT. Gender empowerment and femaleto-male smoking prevalence
  52. ratios. Bull World Health Organ. 2011; 89:195–202.
  53. Ho JE, Scherzer R, Hecht FM, et al. The association of CD4+ T-cell count on
  54. cardiovascular risk in treated HIV disease, AIDS, 2012, vol. 26 (pg. 1115-20).
  55. Kirk GD, Merlo CA. HIV infection in the etiology of lung cancer: confounding, causality,
  56. and consequences, Proc Am Thorac Soc, 2011, vol. 8 (pg. 326-32).
  57. Lekkerkerker AN, van Kooyk Y, Geijtenbeek TB. Viral piracy: HIV-1 targets dendritic cells
  58. for transmission. Curr HIV Res 2006; 4:169–76.
  59. Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, Vandamme AM. Tracing the origin
  60. and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A.
  61. ; 100:6588–6592.
  62. Levy JA. HIV and the Pathogenesis of AIDS. 3rd ed. Washington: ASM Press; 2007.
  63. Lifson A, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR, INSIGHT
  64. SMART Study Group: Smoking-related health risks among person with HIV in the Strategies for
  65. Management of Antiretroviral Therapy clinical trial. Am J Public Health. 2010, 100: 1896-1903.
  66. 2105/AJPH.2009.188664.
  67. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson
  68. HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J,
  69. Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R,
  70. Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, et
  71. al: A comparative risk assessment of burden of disease and injury attributable to 67 risk factor
  72. clusters in 21 regions, 1990-2010: a systematic analysis of the Global Burden of Disease Study
  73. Lancet. 2013, 380: 2224-2260.
  74. Lindayani L, Yeh C-Y, Ko W-C, Ko N-Y. High smoking prevalence among HIVpositive
  75. individuals: a systematic review and meta-analysis. JSubst Use. 2020; 25:1–10.
  76. Luciw PA. Human immunodeficiency viruses and their replication. In: Fields BN, editor.
  77. Virology. 3rd ed. Philadelphia: Lippincott-Raven; 1996. pp. 1881–1952.
  78. Liuzzi G, Chirianni A, Clementi M, Bagnarelli P, Valenza A, Cataldo PT, Piazza M.
  79. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in
  80. a cross-sectional and longitudinal study. AIDS. 1996;10: F51–F56.
  81. Maher D, Wu X, Schacker T, Horbul J, Southern P. HIV binding, penetration, and primary
  82. infection in human cervicovaginal tissue. Proc Natl Acad Sci U S A. 2005; 102:11504–11509.
  83. Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among
  84. individuals living with HIV, AIDS Patient Care STDS, 2002, vol. 16 (pg. 39-42).
  85. Meng G, Wei X, Wu X, Sellers MT, Decker JM, Moldoveanu Z, Orenstein JM, Graham
  86. MF, Kappes JC, Mestecky J, Shaw GM, Smith PD. Primary intestinal epithelial cells selectively
  87. transfer R5 HIV-1 to CCR5+ cells. Nat Med. 2002; 8:150 156.
  88. Momperousse D, Delnevo CD, Lewis MJ. Exploring the seasonality of cigarette-smoking
  89. behaviour. Tob Control. 2007; 16:69–70.
  90. Mourez T, Simon F, Plantier JC. Non-M variants of human immunodeficiency virus type 1.
  91. Clin Microbiol Rev. 2013; 26:448–461.
  92. National Institutes of Health. HIV Infection in Women. May 2006. N.M. Archin, J.M. Sung,
  93. C. Garrido, N. Soriano-Sarabia, D.M. Margolis Eradicating HIV-1 infection: seeking to clear a
  94. persistent pathogenNat Rev Microbiol, 12 (2014), pp. 750-764.
  95. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1
  96. infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr. 2005;
  97. :445–8.
  98. Reynolds NR. Cigarette smoking and HIV: more evidence for action, AIDS Educ Prev,
  99. , vol. 21 (pg. 106-21).
  100. R. Gulick HIV treatment 2020: what will it look like? J Int AIDS Soc, 17 (Suppl. 3) (2014),
  101. p. 19528.
  102. Robbins KE, Lemey P, Pybus OG, Jaffe HW, Youngpairoj AS, Brown TM, Salemi M,
  103. Vandamme AM, Kalish ML. U.S. Human immunodeficiency virus type 1 epidemic: date of
  104. origin, population history, and characterization of early strains. J Virol. 2003; 77:6359–6366.
  105. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect
  106. Med. 2011;1:a006841.
  107. Tebit DM, Arts EJ. Tracking a century of global expansion and evolution of HIV to drive
  108. understanding and to combat disease. Lancet Infect Dis. 2011; 11:45–56.
  109. T.W. Chun, S. Moir, A.S. Fauci HIV reservoirs as obstacles and opportunities for an HIV
  110. cure Nat Immunol, 16 (2015), pp. 584-589.
  111. TurnerJPageShaferKChinDPOsmondDMossarMMarksteinLHuitsingJBarnesSClementeVCh
  112. esneyMAdverse impact of cigarette smoking on dimensions of health-related quality of life in
  113. persons with HIV infection AIDS Patient Care STDS2001151261562411788076.
  114. US Department of Health and Human Services: The Health Consequences of Smoking: A
  115. Report of the Surgeon General. 2004, Atlanta: U.S. Department of Health and Human Services,
  116. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and
  117. Health Promotion, Office on Smoking and Health.
  118. UNAIDS. Global HIV & AIDS statistics — 2019 fact sheet. 2019.
  119. UNAIDS. Understanding fast-track: accelerating action to end the AIDS epidemic by 2030.
  120. 6_JC2743_Understanding_FastTrack_en.pdf. Accessed June 29 2020.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)